electroCore Reports 23% Revenue Growth in Q1 2025 Following NeuroMetrix Acquisition

electroCore, Inc., a bioelectronic technology company, has reported its financial results for Q1 2025, showcasing significant growth and strategic developments. The company achieved a 23% increase in net sales, totaling $6.7 million, compared to the same period in 2024. This was primarily driven by increased sales of its gammaCore TM in the U.S. Department of Veterans Affairs and expansion in international markets. The quarter also marked the closing of electroCore's acquisition of NeuroMetrix, Inc., which contributed approximately $170,000 in unaudited Quell net sales for the period. The acquisition is viewed as a strategic move to expand electroCore's bioelectronic platform. electroCore reported total operating expenses of $9.5 million, with significant investment in selling and marketing efforts. The GAAP net loss stood at $3.9 million for the quarter, which was attributed in part to increased R&D and administrative expenses. Adjusted EBITDA net loss improved slightly to $3.1 million. electroCore's CEO, Dan Goldberger, expressed optimism regarding the company's future, noting that the NeuroMetrix acquisition positions electroCore as a significant player in the non-invasive bioelectronic sector. For the full year of 2025, electroCore anticipates total revenue of $30 million, with NeuroMetrix expected to contribute meaningful revenue by year-end. The company maintains $8 million in cash and securities, down from $12.2 million at the end of 2024. These results and projections highlight electroCore's commitment to growth via strategic acquisitions and market expansion.